Life Science Leader Magazine

Y ou must imagine this scenario because it has not yet come to pass: all patient data from all clinical trials, minus patient identities, made available through an independent "custodian" — an organization charged with administering access to the data based on criteria that ensure all granted requests have a "legitimate scientific purpose." Now, turn back to status quo reality: highly selective or no release of clinical trials data at the total discretion of companies sponsoring the trials, except for disclosures forced by litigation or regulation. October 2013 LifeScienceLeader.com 31

• LSLEAD_ProCov1.pdf
• LSLEAD_ProCov2.pdf
• LSLEAD_COV1.pdf
• LSLEAD_COV2.pdf
• LSLEAD_3.pdf
• LSLEAD_4.pdf
• LSLEAD_5.pdf
• LSLEAD_6.pdf
• LSLEAD_7.pdf
• LSLEAD_8.pdf
• LSLEAD_9.pdf
• LSLEAD_10.pdf
• LSLEAD_11.pdf
• LSLEAD_12.pdf
• LSLEAD_13.pdf
• LSLEAD_14.pdf
• LSLEAD_15.pdf
• LSLEAD_16.pdf
• LSLEAD_17.pdf
• LSLEAD_18.pdf
• LSLEAD_19.pdf
• LSLEAD_20.pdf
• LSLEAD_21.pdf
• LSLEAD_22.pdf
• LSLEAD_23.pdf
• LSLEAD_24.pdf
• LSLEAD_25.pdf
• LSLEAD_26.pdf
• LSLEAD_27.pdf
• LSLEAD_28.pdf
• LSLEAD_29.pdf
• LSLEAD_30.pdf
• LSLEAD_31.pdf
• LSLEAD_32.pdf
• LSLEAD_33.pdf
• LSLEAD_34.pdf
• LSLEAD_35.pdf
• LSLEAD_36.pdf
• LSLEAD_37.pdf
• LSLEAD_38.pdf
• LSLEAD_39.pdf
• LSLEAD_40.pdf
• LSLEAD_41.pdf
• LSLEAD_42.pdf
• LSLEAD_43.pdf
• LSLEAD_44.pdf
• LSLEAD_45.pdf
• LSLEAD_46.pdf
• LSLEAD_47.pdf
• LSLEAD_48.pdf
• LSLEAD_49.pdf
• LSLEAD_50.pdf
• LSLEAD_51.pdf
• LSLEAD_52.pdf
• LSLEAD_53.pdf
• LSLEAD_54.pdf
• LSLEAD_55.pdf
• LSLEAD_56.pdf
• LSLEAD_57.pdf
• LSLEAD_58.pdf
• LSLEAD_59.pdf
• LSLEAD_60.pdf
• LSLEAD_61.pdf
• LSLEAD_62.pdf
• LSLEAD_63.pdf
• LSLEAD_64.pdf
• LSLEAD_65.pdf
• LSLEAD_66.pdf
• LSLEAD_COV3.pdf
• LSLEAD_COV4.pdf